Glesatinib (MGCD-265) is a tyrosine kinase inhibitor that potently and selectively inhibits Met and Axl kinase..

Gln-AMS (TFA) is a type Ia aminoacyl-tRNA synthetase (AARS) inhibitor. Gln-AMS inhibits glutaminyl-tRNA synthetase (GlnRS) with a Ki of 1.32 µM.

Gln-AMS is an aminoacyl-tRNA synthetases (AARS) inhibitor, which binds the A-domain within the NRPS enzymes.

GLP-1 receptor agonist-1 is a glucagon-like peptide-1 receptor (GLP-1R) agonist.

GLP-1(7-36) is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.

GLPG 0974 is a potent, selective free fatty acid receptor 2 (FFA2, GPR43) antagonist with IC50 of 95 nM.

GLPG-2222 (ABBV-2222, Galicaftor) is a novel potent and efficacious CFTR corrector with EC50 of 5 nM.

GLS1 inhibitor is an inhibitor of glutaminase 1

GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations.

Glucokinase activator 1 is a liver-directed glucokinase activator with an EC50 of 34 nM.

Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.

Glycodeoxycholate Sodium is a bile salt.

Glycodeoxycholic acid monohydrate is a nuclear receptor ligand.

Glycogen is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria.

Glycopyrronium bromide (CHF 5259) is a peripherally-acting quaternary ammonium antimuscarinic agent with little or no central nervous system activity.

GlyT1 inhibitor 46 is a novel potent, selective, orally available inhibitor of glycine transporter-1 (GlyT1) with IC50 of 38 and 21 nM for rat and human GlyT1, respectively.

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.

GMI-1070 (Rivipansel, PF-06460031) is a novel small molecule glycomimetic pan-Selectin antagonist with IC50 of 4.3 uM, 423 uM and 337 uM for E-selectin, P-selectin and L-selectin, respectively.

GNA002 (GNA-002) is a gambogenic acid (GNA) derivative that specifically and covalently binds to Cys668 within the EZH2-SET domain, trigges EZH2 degradation (IC50=1.1 uM) through COOH terminus of Hsp70-interacting protein (CHIP)-mediated ubiquitination.

GNE 220 (Hydrochloride) is a potent and selective inhibitor of MAP4K4, with an IC50 of 7 nM.

GNE-0439 is a novel potent, selective inhibitor of Nav1.7 channel with IC50 of 0.34 uM, shows high selectivity over Nav1.5 (IC50=38.3 uM).